{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:30:28Z","timestamp":1740148228411,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To report healthcare resource use and associated costs in controlled versus uncontrolled carcinoid syndrome (CS) in patients with neuroendocrine tumours.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cross-sectional, non-interventional multicentre study was conducted with retrospective data analysis. Resource use was compared between two patient groups: those with controlled CS (&gt;\u200912\u00a0months with no uncontrolled CS episodes) and uncontrolled CS (&lt;\u200912\u00a0months since last uncontrolled episode). Patients were matched for age, sex, and origin and grade of tumour. When no matching patients were available, data from deceased patients were used. Information on healthcare resource use came from review of medical records, patient history and physician reports. Working capacity was assessed using the Work Productivity and Activity Impairment General Health questionnaire.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-six university hospitals in Spain participated, between July 2017 and April 2018. 137 patients were enrolled; 104 were analysed (2 groups of 52). Patients with uncontrolled CS had 10 times more emergency department (ED) visits (mean 1.0 vs 0.10 visits; <jats:italic>P<\/jats:italic>\u2009=\u20090.0167), were more likely to have a hospital admission (40.4% vs 19.2%; <jats:italic>P<\/jats:italic>\u2009=\u20090.0116) and had longer hospital stays (mean 7.87 vs 2.10\u00a0days; <jats:italic>P<\/jats:italic>\u2009=\u20090.0178) than those with controlled CS. This corresponded to higher annual hospitalisation costs (mean \u20ac5511.59 vs \u20ac1457.22; <jats:italic>P<\/jats:italic>\u2009=\u20090.028) and ED costs (\u20ac161.25 vs \u20ac14.85; <jats:italic>P<\/jats:italic>\u2009=\u20090.0236). The mean annual total healthcare costs were 60.0% higher in patients with uncontrolled than controlled CS (<jats:italic>P<\/jats:italic>\u2009=\u2009NS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study quantifies higher health resource use, and higher hospitalisation and ED costs in patients with uncontrolled CS. Better control of CS may result 3in lower medical costs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12094-021-02608-7","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T16:04:33Z","timestamp":1623254673000},"page":"2046-2056","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7287-4060","authenticated-orcid":false,"given":"A.","family":"Custodio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Jimenez-Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Carmona-Bayonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. I.","family":"Del Olmo-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. \u00c1.","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Canal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"De la Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Villabona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"issue":"1","key":"2608_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1200\/JGO.2015.002980","volume":"3","author":"S Singh","year":"2016","unstructured":"Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2016;3(1):43\u201353. https:\/\/doi.org\/10.1200\/JGO.2015.002980 (Published 2016 Jun 8).","journal-title":"J Glob Oncol"},{"issue":"10","key":"2608_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589.","journal-title":"JAMA Oncol"},{"issue":"4","key":"2608_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589\u201397. https:\/\/doi.org\/10.1002\/cncr.29099.","journal-title":"Cancer"},{"issue":"Suppl 1","key":"2608_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000080731","volume":"80","author":"BG Taal","year":"2004","unstructured":"Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80(Suppl 1):3\u20137. https:\/\/doi.org\/10.1159\/000080731.","journal-title":"Neuroendocrinology"},{"issue":"12","key":"2608_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991\u20131002. https:\/\/doi.org\/10.1016\/j.neo.2017.09.002.","journal-title":"Neoplasia"},{"issue":"6","key":"2608_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1159\/000085237","volume":"80","author":"U Pl\u00f6ckinger","year":"2004","unstructured":"Pl\u00f6ckinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004;80(6):394\u2013424. https:\/\/doi.org\/10.1159\/000085237.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"2608_CR7","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ecl.2017.04.004","volume":"46","author":"V Aluri","year":"2017","unstructured":"Aluri V, Dillon JS. Biochemical testing in neuroendocrine tumors. Endocrinol Metab Clin N Am. 2017;46(3):669\u201377. https:\/\/doi.org\/10.1016\/j.ecl.2017.04.004.","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"3","key":"2608_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/jso.20179","volume":"89","author":"O Rorstad","year":"2005","unstructured":"Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89(3):151\u201360. https:\/\/doi.org\/10.1002\/jso.20179.","journal-title":"J Surg Oncol"},{"issue":"Suppl 7","key":"2608_CR9","doi-asserted-by":"publisher","first-page":"vii124","DOI":"10.1093\/annonc\/mds295","volume":"23","author":"K \u00d6berg","year":"2012","unstructured":"\u00d6berg K, Knigge U, Kwekkeboom D, Perren A, ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii124\u201330. https:\/\/doi.org\/10.1093\/annonc\/mds295.","journal-title":"Ann Oncol"},{"issue":"4","key":"2608_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","volume":"18","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(17)30110-9.","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2608_CR11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.6061\/clinics\/2018\/e490s","volume":"73","author":"AC Rubin de Celis Ferrari","year":"2018","unstructured":"Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018;73(suppl 1):490. https:\/\/doi.org\/10.6061\/clinics\/2018\/e490s.","journal-title":"Clinics (Sao Paulo)"},{"issue":"5","key":"2608_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1530\/ERC-14-0173","volume":"21","author":"MH Kulke","year":"2014","unstructured":"Kulke MH, O\u2019Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014;21(5):705\u201314. https:\/\/doi.org\/10.1530\/ERC-14-0173.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2608_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000335597","volume":"95","author":"M Pavel","year":"2012","unstructured":"Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157\u201376. https:\/\/doi.org\/10.1159\/000335597.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2608_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.seminoncol.2012.11.006","volume":"40","author":"C Toumpanakis","year":"2013","unstructured":"Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol. 2013;40(1):56\u201368. https:\/\/doi.org\/10.1053\/j.seminoncol.2012.11.006.","journal-title":"Semin Oncol"},{"issue":"4","key":"2608_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.clon.2011.08.006","volume":"24","author":"KE Oberg","year":"2012","unstructured":"Oberg KE. The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol (R Coll Radiol). 2012;24(4):282\u201393. https:\/\/doi.org\/10.1016\/j.clon.2011.08.006.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"9","key":"2608_CR16","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.4158\/EP151172.OR","volume":"22","author":"AI Vinik","year":"2016","unstructured":"Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA, ELECT Study Group. Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (elect): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22(9):1068\u201380. https:\/\/doi.org\/10.4158\/EP151172.OR.","journal-title":"Endocr Pract."},{"issue":"9","key":"2608_CR17","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1007\/s00520-016-3189-z","volume":"24","author":"TP Pearman","year":"2016","unstructured":"Pearman TP, Beaumont JL, Cella D, Neary MP, Yao J. Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Support Care Cancer. 2016;24(9):3695\u2013703. https:\/\/doi.org\/10.1007\/s00520-016-3189-z.","journal-title":"Support Care Cancer"},{"issue":"3","key":"2608_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","volume":"41","author":"JL Beaumont","year":"2012","unstructured":"Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461\u20136. https:\/\/doi.org\/10.1097\/MPA.0b013e3182328045.","journal-title":"Pancreas"},{"key":"2608_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7525-5-18","volume":"5","author":"C Fr\u00f6jd","year":"2007","unstructured":"Fr\u00f6jd C, Larsson G, Lampic C, von Essen L. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes. 2007;5:18. https:\/\/doi.org\/10.1186\/1477-7525-5-18.","journal-title":"Health Qual Life Outcomes."},{"issue":"12","key":"2608_CR20","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1634\/theoncologist.2017-0149","volume":"22","author":"C Shen","year":"2017","unstructured":"Shen C, Chu Y, Halperin DM, et al. Carcinoid syndrome and costs of care during the first year after diagnosis of neuroendocrine tumors among elderly patients. Oncologist. 2017;22(12):1451\u201362. https:\/\/doi.org\/10.1634\/theoncologist.2017-0149.","journal-title":"Oncologist"},{"issue":"6","key":"2608_CR21","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.3748\/wjg.v22.i6.2118","volume":"22","author":"MS Broder","year":"2016","unstructured":"Broder MS, Chang E, Romanus D, Cherepanov D, Neary MP. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. World J Gastroenterol. 2016;22(6):2118\u201325. https:\/\/doi.org\/10.3748\/wjg.v22.i6.2118.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"2608_CR22","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/13696998.2017.1337019","volume":"20","author":"L Huynh","year":"2017","unstructured":"Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB. Cost reduction from resolution\/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. J Med Econ. 2017;20(9):945\u201351. https:\/\/doi.org\/10.1080\/13696998.2017.1337019.","journal-title":"J Med Econ"},{"issue":"12","key":"2608_CR23","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1080\/00365521.2018.1531653","volume":"53","author":"E Les\u00e9n","year":"2018","unstructured":"Les\u00e9n E, Bj\u00f6rstad \u00c5, Bj\u00f6rholt I, et al. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study. Scand J Gastroenterol. 2018;53(12):1509\u201318. https:\/\/doi.org\/10.1080\/00365521.2018.1531653.","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"2608_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006.","journal-title":"Pharmacoeconomics"},{"key":"2608_CR25","unstructured":"Website: http:\/\/www.reillyassociates.net\/WPAI_Scoring.html. Accessed 02 Jul 2020."},{"issue":"2","key":"2608_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/pds.1471","volume":"17","author":"ISPE","year":"2008","unstructured":"ISPE. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17(2):200\u20138. https:\/\/doi.org\/10.1002\/pds.1471.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2608_CR27","unstructured":"Website: http:\/\/esalud.oblikue.com\/ (website in Spanish). Accessed 02 Jul 2020.."},{"key":"2608_CR28","unstructured":"Website: https:\/\/botplusweb.portalfarma.com\/ (website in Spanish). Accessed 02 Jul 2020"},{"issue":"9808","key":"2608_CR29","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(11)61742-X.","journal-title":"Lancet"},{"issue":"2","key":"2608_CR30","doi-asserted-by":"publisher","first-page":"e12983","DOI":"10.1111\/ecc.12983","volume":"28","author":"E Les\u00e9n","year":"2019","unstructured":"Les\u00e9n E, Granfeldt D, Houchard A, et al. Cost-of-illness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden-A population-based register-linkage study. Eur J Cancer Care (Engl). 2019;28(2):e12983. https:\/\/doi.org\/10.1111\/ecc.12983.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"6","key":"2608_CR31","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11136-009-9487-x","volume":"18","author":"T Haugland","year":"2009","unstructured":"Haugland T, Vatn MH, Veenstra M, Wahl AK, Natvig GK. Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Qual Life Res. 2009;18(6):719\u201326. https:\/\/doi.org\/10.1007\/s11136-009-9487-x.","journal-title":"Qual Life Res"},{"issue":"7","key":"2608_CR32","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/02841860152703445","volume":"40","author":"G Larrson","year":"2001","unstructured":"Larrson G, Sj\u00f6den PO, \u00d6berg K, Eriksson B, Von Essen L. Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours. Acta Oncol. 2001;40(7):825\u201331. https:\/\/doi.org\/10.1080\/02841860152703445.","journal-title":"Acta Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02608-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-021-02608-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02608-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T21:25:34Z","timestamp":1630013134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-021-02608-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2608"],"URL":"https:\/\/doi.org\/10.1007\/s12094-021-02608-7","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"type":"print","value":"1699-048X"},{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"22 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PJF: travel grants from Ipsen and consulting\/advisory role for Bristol, Mylan, Rovi, LeoPharma, ADACAP, all outside of the scope of this work; ACB: travel grants and honoraria from Ipsen, Roche and Novartis and consulting\/advisory role for Roche, Rovi, LeoPharma, Pfizer, Esteve, Elsevier, Bristol, all outside of the scope of this work; MIDO: honoraria and\/or research grants and\/or advisory board and\/or consultancy fees from ADACAP, Ipsen, Novartis, Pfizer; IL: honoraria and\/or congress support from Bristol Myers, Novartis, Pfizer, Pierre Fabre, Roche; J\u00c1D: Ipsen advisory board; NC: employee of IQVIA; MP, GDLC: employees of Ipsen; ACB: honoraria and\/or advisory board from BMS, Ipsen, MSD, Novartis, Pfizer; CV, MJG: nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Where patient data can be anonymised, Ipsen will share all individual participant data that underlie the results reported in this article with qualified researchers who provide a valid research question. Study documents, such as the study protocol and clinical study report, are not always available. Proposals should be submitted to DataSharing@Ipsen.com and will be assessed by a scientific review board. Data are available beginning 6\u00a0months and ending 5\u00a0years after publication; after this time, only raw data may be available.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This non-interventional study was approved by the Ethics Committee of <i>Hospital Universitari de Bellvitge,<\/i> Barcelona (27 April 2017), and classified as a post-approval study by the Spanish Agency for Medicines and Medical Devices (AEMPS; 16 February 2017). The study followed the International Society for Pharmacoepidemiology Guidelines on Good Pharmacoepidemiological Practice []. Prior to any data collection, living participants received a full explanation and provided written informed consent. In the case of deceased participants, following ethics committee review, consent from living relatives was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Subjects signed the informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}